Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridion for reversal of deep neuromuscular blockade in children
NCT01809886Phase 3Completed
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Oct 2011
- Primary completion
- Oct 2013
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Time to T4/T1 ratio > 0.9 at 10 hours. Started Oct 2011; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT01809886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01809886.